Structure Therapeutics Inc. focuses on developing oral small molecules against GPCR targets, aiming to overcome the limitations of injectable biologics. Its lead candidate, aleniglipron, an oral GLP-1 receptor agonist for obesity and related conditions, is advancing towards Phase 3 studies with encouraging Phase 2 data supporting differentiated efficacy and safety. The firm’s technology platform integrates advanced structural biology and computational chemistry, enabling selective drug design and pipeline expansion across metabolic and chronic indications. While operating losses continue as clinical development progresses, the company maintains robust liquidity and strategic collaborations to sustain growth and innovation.